PCC0208057 as a small molecule inhibitor of TRPC6 in the treatment of prostate cancer
Prostate cancer (PCa) is a common malignant tumor, whose morbidity and mortality keep the top three in the male-related tumors in developed countries. Abnormal ion channels, such as transient receptor potential canonical 6 (TRPC6), are reported to be involved in the carcinogenesis and progress of pr...
| Główni autorzy: | , , , , , , , , |
|---|---|
| Format: | Artykuł |
| Język: | English |
| Wydane: |
Frontiers Media S.A.
2024-03-01
|
| Seria: | Frontiers in Pharmacology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1352373/full |